SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bal Pharma moves up on entering into collaboration with Akaal Pharma

07 Mar 2018 Evaluate

Bal Pharma is currently trading at Rs. 92.90, up by 0.15 points or 0.16% from its previous closing of Rs. 92.75 on the BSE.

The scrip opened at Rs. 95.00 and has touched a high and low of Rs. 95.20 and Rs. 92.00 respectively. So far 6823 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 128.00 on 01-Jan-2018 and a 52 week low of Rs. 84.45 on 06-Feb-2018.

Last one week high and low of the scrip stood at Rs. 96.00 and Rs. 92.00 respectively. The current market cap of the company is Rs. 130.39 crore.

The promoters holding in the company stood at 44.57%, while Institutions and Non-Institutions held 0.13% and 55.30% respectively.

Bal Pharma has entered into collaboration with Akaal Pharma, Melbourne, Australia whereby both companies have launched a Joint Venture Company (JVC) - AB VET Pharma. The new joint venture will be completely funded by Bal Pharma to develop Akaal Pharma’s IP within the veterinary field.

The first veterinary indication will be against atopic dermatitis (AD) in dogs. Akaal’s ABV-119 is the first of its kind oral drug candidate for the treatment of AD in dogs. ABV-119 is a multimodal therapy that includes anti-inflammatory/ immune modulatory and anti-itch effects. AB VET plans to begin clinical development in H1 2018.

Bal Pharma is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.


Bal Pharma Share Price

78.47 0.37 (0.47%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×